CYTK is Cytokinetics, Incorporated (Healthcare) — a non-dividend-paying stock. Trading at $71.93. Market cap: $9.93B. Capital Quality Rank: 49/100 — Stagnant mediocrity.
Stock snapshot
| Price | $71.93 |
| Market cap | $9.93B |
| Sector | Healthcare |
| Exchange | NMS |
| Pays dividend | No |
Capital Quality & fundamentals
DiviDrip's Capital Analytics engine ranks every non-dividend stock 1-100 on a 4-factor composite (Shareholder Yield 30%, Cash-Flow ROI 25%, Operating Momentum 25%, Tail-Risk 20%) — sector-neutralized so a biotech isn't penalized for negative earnings the way a utility would be.
| Capital Quality Rank (1-100) | 49 / 100 · Stagnant mediocrity |
| ROIC (TTM) | -144.9% |
| Revenue CAGR (3y) | -2.4% |
| Shareholder buyback yield | -6.76% |
| Altman Z-score zone | Distress |
About CYTK
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Related non-dividend companies
Other non-dividend stocks investors research alongside CYTK. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is CYTK's current stock price?
CYTK (Cytokinetics, Incorporated) is currently trading at $71.93.
Does CYTK pay a dividend?
CYTK (Cytokinetics, Incorporated) does not currently pay a regular dividend.
What is CYTK's Capital Quality Rank?
CYTK has a Capital Quality Rank of 49/100 — Stagnant mediocrity. This score blends ROIC, revenue growth, buybacks, and balance-sheet health.
Track CYTK in DiviDrip
Add CYTK to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search CYTK and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-02. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.